T. Rowe Price Health Sciences Fund, Inc.
Actively managed U.S. stock fund
As of its 2026 Q2 report, T. Rowe Price Health Sciences Fund, Inc. held 279 positions with $11.95B in net assets. Its ten largest holdings made up 47.6% of the fund. The PRHSX share class costs 0.8% a year. Over the 12 months to May 2026, PRHSX returned 24.3%, with dividends reinvested. In 2026 Q2 it added 39 new positions and exited 47.
The fund seeks long-term capital appreciation.
The fund invests at least 80% of assets in common stocks of health sciences companies—pharmaceutical firms, biotechnology companies, medical device makers, and health care services providers—using fundamental bottom-up analysis to identify high-quality growth companies or, when valuations appear elevated, undervalued opportunities. The fund may also hold foreign stocks and recently public or privately held companies. Because the fund's allocation among the four health sciences areas varies with the adviser's outlook, its sector exposure will shift over time.
What you own
| Company | Weight | Value | Shares | Reported price |
|---|---|---|---|---|
14.28% | $1.71B | 1.4M | $1,199.43 | |
6.63% | $792.01M | 3.1M | $253.97 | |
5.99% | $715.61M | 1.7M | $415.63 | |
ABBVABBVIE INC | 5.10% | $609.30M | 2.4M | $251.64 |
4.01% | $478.73M | 3.7M | $128.50 | |
2.82% | $336.99M | 2.7M | $126.34 | |
2.52% | $301.21M | 600.8K | $501.36 | |
2.28% | $272.28M | 548.1K | $496.73 | |
2.11% | $251.85M | 4.4M | $57.62 | |
1.89% | $225.34M | 2.5M | $90.74 |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
The 200 largest of 279 holdings, with the share counts as filed, open with a free account.
What the fund is made of
Percentages are of fund net assets. Rounding, liabilities and short positions can make totals differ from 100%.
| Stocks | 99.36% |
| Cash & short-term | 0.65% |
| Bonds | 0.15% |
By sector
- Health Care
- 91.1%
- Other
- 4.4%
- International
- 3.8%
- Cash
- 0.6%
How it has done
PRHSX share class · total returns with dividends reinvested
Volatility over the last 12 months: 14.56%. Past returns are a record, not a forecast.
Jun 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
The 2 share classes hold the same portfolio
| Share class | Expense ratio | 1 year | 3 years | 5 years | Worst fall |
|---|---|---|---|---|---|
| 0.80% | +24.33% | +24.08% | +16.92% | -18.45% | |
| 0.67% | +24.50% | +24.58% | +17.64% | -18.36% |
These classes hold the same portfolio, so the 0.72pp spread over 5 years is the cost difference between them — roughly 0.14pp a year — not a difference in what they own.
Fees & fund details
T. Rowe Price Health Sciences Fund, Inc. is an actively managed U.S. equity fund. 31% of PRHSX’s stock holdings are in companies whose revenue grew in the top quartile of U.S. companies over the last five fiscal years (covering 82% of the fund’s equity).
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
- Expense ratio, by class
- 0.67% – 0.80%· PRHSX 0.80%
- Portfolio turnover
- 61.60% a year · as of 2026 Q1
Turnover is how much of the portfolio was replaced in a year.
Classified from what the fund holds, not from its name · 2026 Q2. The summary is a paraphrase of the prospectus; the objective is verbatim.
What changed this quarter
Positions that entered or left the fund since its previous filing. Positions that were only resized are not listed.
39 new· the largest 8
47 exited· the largest 8
Debt profile
What this fund holds — value-weighted across its bond and securitized long positions · as of 2026-06-30
Share of the fund's debt by how its coupon behaves — the fact that decides whether a rate move reaches this portfolio at all.
| Fixed rate | 81.1% |
| Zero-coupon or unclassified | 18.9% |
Share of the fund's debt value in each maturity band, shortest first.
| <1y | 26.3% |
| 3-5y | 73.7% |
Based on what filers reported; a filer that never reported a flag also reads as none.
Risk profile
Interest-rate and credit-spread sensitivity, both in years · as of 2026Q2
This fund filed the credit-spread disclosure and reported no sensitivity — measured, and the answer is none.
Show the numbers
| Tenor | Rate yrs | IG yrs | HY yrs | IG $/bp | HY $/bp |
|---|---|---|---|---|---|
| 3 mo | +0.00 | +0.00 | +0.00 | $0 | $0 |
| 1 yr | +0.00 | +0.00 | +0.00 | $0 | $0 |
| 5 yr | +0.00 | +0.00 | +0.00 | $0 | $0 |
| 10 yr | +0.00 | +0.00 | +0.00 | $0 | $0 |
| 30 yr | +0.00 | +0.00 | +0.00 | $0 | $0 |
Dollar change per 1bp of spread movement, as filed and sign-anchored. A blank cell was not filed; a zero was.
Understand how this fund fits with the rest.
Explore shared holdings, compare funds and follow their businesses with your connected AI:
- “Where do my funds overlap — PRHSX, QQQ and the fund in my 401(k)?”
- “How do this fund’s ten biggest holdings stack up against each other?”
- “For my target-date fund, what’s the real stock-and-bond mix once you look through it?”